Revision of USP Chapter on IR Spectroscopy
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
In the Pharmacopeial Forum No 39(2), the USP has published the draft for the revised General Chapter <854> on Mid-Infrared Spectroscopy. This draft is the second one and takes into consideration the comments sent to the USP.
Some acceptance criteria for some of the single validation parameters have been adapted in the validation of IR methods. Regarding accuracy, the recovery rate has been added to 95.0% - 105.0% for drug product assay.
Regarding precision, the relative standard deviation for repeatability is set as follows:
- Not more than 1.0% for APIs
- Not more than 2.0% for medicinal products
- Not more than 20.0% for impurities
And for intermediate precision:
- Not more than 1.0% for APIs
- Not more than 3.0% for medicinal products
- Not more than 25.0% for impurities
In addition to revised Chapter <854>, there will also be the new General USP Chapter <1854> which describes theory and practice of Mid Infrared Spectroscopy.
Both documents can be found on the Pharmacopeial Forum of the USP website.
Related GMP News
19.08.2026FDA Warning Letter: Averaging Data to Override OOS Findings
12.08.2026ECA's Analytical Control Group Publishes Detailed Report on OOS Survey
12.08.2026BP Publishes Key Insights on Limits in Chromatographic Tests
04.08.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
04.08.2026USP AISQ Virtual Workshop: ECA AQCG Board Members Contributed as Speakers
04.08.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products


